Oruka Therapeutics, Inc. ORKA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$31.82M-7.6% | -$29.58M+2.3% | -$30.28M-23.2% | -$24.57M-17.0% | -$21M+74.9% | ||
| $43K+53.6% | $28K+40.0% | $20K+5.3% | $19K+18.8% | $16K-40.7% | ||
| $6.97M+69.3% | $4.12M-59.5% | $10.17M+100% | $5.08M+4.0% | $4.88M-67.3% | ||
| -$1.3M-159% | $2.21M-54.1% | $4.81M— | —— | $2.32M-29.6% | ||
| —— | —— | —— | —— | $60K+39.5% | ||
| -$493K-125% | $1.95M+179% | -$2.46M-319% | $1.12M+1,248% | $83K-97.6% | ||
| -$125K— | $0+100% | -$439K-5,388% | -$8K+61.9% | -$21K-50.0% | ||
| -$23.58M-4.4% | -$22.59M-4.6% | -$21.6M+6.7% | -$23.15M-10.9% | -$20.87M+63.9% | ||
| $73K+15.9% | $63K-36.4% | $99K+191% | $34K+162% | $13K-93.1% | ||
| $90.83M-10.1% | $100.99M-62.3% | $267.68M+148% | $108M+144% | $44.29M-86.6% | ||
| $76.47M-3.2% | $79.03M-45.6% | $145.33M+28.7% | $112.89M+29.5% | $87.17M— | ||
| $29.15M+5.4% | $27.64M-4.7% | $28.99M+20.3% | $24.09M+20.9% | $19.93M-73.5% | ||
| -$14.44M+34.4% | -$22.02M+82.0% | -$122.45M-2,620% | $4.86M-88.7% | $42.87M+113% | ||
| $1.7M+202% | $562K— | —— | —— | —— | ||
| $40.6M+13,524% | $298K-99.8% | $169.91M— | —— | —— | ||
| $2.59M+106% | -$44.32M-271% | $25.86M+242% | -$18.18M-183% | $22M-64.3% | ||
| $446K-32.7% | $663K-36.3% | $1.04M-30.8% | $1.5M-16.4% | $1.8M-20.0% | ||
| $6.97M+69.3% | $4.12M-59.5% | $10.17M+100% | $5.08M+4.0% | $4.88M-67.3% | ||
| $43K+53.6% | $28K+40.0% | $20K+5.3% | $19K+18.8% | $16K-40.7% | ||
| $3M— | $0+100% | -$111K+84.1% | -$698K+86.6% | -$5.21M-186% | ||
| -$1.3M-159% | $2.21M-54.1% | $4.81M— | —— | $2.32M-29.6% | ||
| -$125K— | $0+100% | -$439K-5,388% | -$8K+61.9% | -$21K-50.0% | ||
| -$493K-125% | $1.95M+179% | -$2.46M-319% | $1.12M+1,248% | $83K-97.6% | ||
| -$461K-157% | $805K-66.5% | $2.4M+289% | $617K+317% | $148K-86.9% | ||
| —— | —— | —— | —— | —— | ||
| $38.9M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3M— | —— | —— | —— | $2.12M— | ||
| $7.29M+7.3% | $6.79M+32.7% | $5.12M+17.8% | $4.34M-15.9% | $5.16M-60.5% | ||
| —— | $13.5K0.0% | $13.5K0.0% | $13.5K0.0% | $13.5K-82.2% | ||
| —— | $237.25K0.0% | $237.25K0.0% | $237.25K0.0% | $237.25K+132% | ||
| $4.61M-5.0% | $4.85M+26.5% | $3.83M-0.6% | $3.86M-5.7% | $4.09M-30.2% | ||
| $143K— | —— | —— | —— | $62K-51.2% | ||
| $4.61M-4.8% | $4.85M+26.6% | $3.83M-0.7% | $3.86M-5.7% | $4.09M-7.1% | ||
| -$1.03M-384% | $361K+70.3% | $212K+1,110% | -$21K-160% | $35K+185% | ||
| —— | $2.52M0.0% | $2.52M0.0% | $2.52M0.0% | $2.52M-75.7% | ||
| -$23.65M-4.4% | -$22.66M-4.4% | -$21.7M+6.4% | -$23.18M-11.0% | -$20.88M+64.0% | ||
| -$23.65M-4.4% | -$22.66M-4.4% | -$21.7M+6.4% | -$23.18M-11.0% | -$20.88M+64.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Oruka Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.